AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29889671 — intervention group
Group type: EXPERIMENTAL
Intervention: mDSE in female patients
Number of subjects: 301
Study 29889671 — intervention group
Group type: EXPERIMENTAL
Intervention: mDSE in male patients
Number of subjects: 301
Study 29889671 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound assessments at the level of vocal cords
Number of subjects: 301
Study 29889751 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient transcervical catheter placement
Number of subjects: 129
Study 29889751 — intervention group
Group type: COMPARATOR
Intervention: Inpatient transcervical catheter placement with concomitant oxytocin infusion
Number of subjects: 129
Study 29889830 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal Resistive Index (RRI) measured on ICU admission
Number of subjects: 99
Study 29889830 — intervention group
Group type: EXPERIMENTAL
Intervention: RRI for AKI stage 2
Number of subjects: 99
Study 29889830 — intervention group
Group type: EXPERIMENTAL
Intervention: RRI for AKI stage 3
Number of subjects: 99
Study 29889830 — intervention group
Group type: EXPERIMENTAL
Intervention: RRI for AKI stage 1
Number of subjects: 99
Study 29889830 — intervention group
Group type: EXPERIMENTAL
Intervention: Univariate analysis of RRI
Number of subjects: 99
Study 29889830 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis of RRI
Number of subjects: 99
Study 29889987 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental assessment using a three-item visual analogue scale (VAS) concerning Activity, Feeding, and Illness.
Number of subjects: 267
Study 29890123 — intervention group
Group type: EXPERIMENTAL
Intervention: Weston CAC score
Number of subjects: 1875
Study 29890123 — intervention group
Group type: EXPERIMENTAL
Intervention: Agatston CAC score
Number of subjects: 1875
Study 29890123 — intervention group
Group type: COMPARATOR
Intervention: Baseline CAD
Number of subjects: 1875
Study 29890123 — intervention group
Group type: COMPARATOR
Intervention: Incident CVD
Number of subjects: 1875
Study 29890128 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone treatment for 3 months
Number of subjects: 11
Study 29890128 — intervention group
Group type: COMPARATOR
Intervention: Endometrium not displaying PAEC (control group)
Number of subjects: 11
Study 29890186 — intervention group
Group type: EXPERIMENTAL
Intervention: BOLD response in the medial prefrontal cortex for anticipating food compared to money
Number of subjects: 59
Study 29890186 — intervention group
Group type: EXPERIMENTAL
Intervention: BOLD response in the dorsolateral prefrontal cortex for winning food compared to money
Number of subjects: 59
Study 29890238 — intervention group
Group type: EXPERIMENTAL
Intervention: Midostaurin
Number of subjects: 0
Study 29890330 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular Space Occupancy (VASO) imaging at 9.4 T
Number of subjects: 0
Study 29890330 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 29890508 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment
Number of subjects: 226
Study 29890892 — intervention group
Group type: EXPERIMENTAL
Intervention: Group sequential procedure based on the asymptotic covariance of the sequence of Wald statistics
Number of subjects: 4600
Study 29890892 — intervention group
Group type: EXPERIMENTAL
Intervention: Group sequential procedure based on the canonical joint distribution
Number of subjects: 4600
Study 29890960 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentalisation-based treatment (MBT)
Number of subjects: 75
Study 29891238 — intervention group
Group type: EXPERIMENTAL
Intervention: s-cTnI Architect
Number of subjects: 2601
Study 29891238 — intervention group
Group type: EXPERIMENTAL
Intervention: s-cTnI Ultra
Number of subjects: 2601
Study 29891238 — intervention group
Group type: EXPERIMENTAL
Intervention: s-cTnI Accu
Number of subjects: 2601
Study 29891238 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnI Accu
Number of subjects: 2601
Study 29891470 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated and personalized practitioner-led method (gene test results plus integrated and personalized nutrition report)
Number of subjects: 55
Study 29891470 — intervention group
Group type: COMPARATOR
Intervention: Control group (gene test results report emailed)
Number of subjects: 55
Study 29891609 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous solithromycin (6 to 8 mg/kg of body weight)
Number of subjects: 84
Study 29891609 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral solithromycin (14 to 16 mg/kg on days 1 and 7; 10 to 15 mg/kg on days 2 to 5)
Number of subjects: 84
Study 29891610 — intervention group
Group type: EXPERIMENTAL
Intervention: Doravirine 100 mg
Number of subjects: 0
Study 29891853 — intervention group
Group type: COMPARATOR
Intervention: Methylated DNA markers (MDMs) assessed by quantitative methylation specific PCR (qMSP) on tissue samples.
Number of subjects: 62
Study 29891853 — intervention group
Group type: COMPARATOR
Intervention: Whole esophageal brushings with selected MDMs.
Number of subjects: 62
Study 29891853 — intervention group
Group type: COMPARATOR
Intervention: Capsule sponge (25 mm, 10 pores or 20 pores per inch) swallowed by patients.
Number of subjects: 62
Study 29891853 — intervention group
Group type: COMPARATOR
Intervention: 2-marker panel (VAV3 + ZNF682) for BE discrimination.
Number of subjects: 62
Study 29892208 — intervention group
Group type: EXPERIMENTAL
Intervention: Procarbazine and CCNU chemotherapy
Number of subjects: 8
Study 29893698 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Hemoglobin (Hb) levels in patients with NAFLD
Number of subjects: 1186
Study 29893698 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with NAFLD
Number of subjects: 1186
Study 29893797 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted H1N1pdm09 vaccine
Number of subjects: 250
Study 29893797 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal vaccinations (repeated and occasional groups)
Number of subjects: 250
Study 29893797 — intervention group
Group type: COMPARATOR
Intervention: Single group (no seasonal vaccination)
Number of subjects: 250
Study 29895073 — intervention group
Group type: EXPERIMENTAL
Intervention: G-POEM
Number of subjects: 20
Study 29895178 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV/MVA-BN-Filo prime-boost Ebola vaccine regimen
Number of subjects: 0
Study 29895247 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippocampal mean diffusivity (MD) measured by Diffusion-Tensor Imaging in primary care patients
Number of subjects: 140
Study 29895247 — intervention group
Group type: COMPARATOR
Intervention: Hippocampal mean diffusivity (MD) measured by Diffusion-Tensor Imaging in specialized care patients
Number of subjects: 140
Study 29895259 — intervention group
Group type: EXPERIMENTAL
Intervention: Real stimulation using CTU Mega 20 device (200 J, 2 Tesla)
Number of subjects: 0
Study 29895259 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 29895259 — intervention group
Group type: EXPERIMENTAL
Intervention: Real stimulation using CTU Mega 20 device
Number of subjects: 0
Study 29895331 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV) as first-line treatment
Number of subjects: 584
Study 29895331 — intervention group
Group type: COMPARATOR
Intervention: Hospital mortality
Number of subjects: 584
Study 29895331 — intervention group
Group type: COMPARATOR
Intervention: Limiting life-sustaining measures
Number of subjects: 584
Study 29895331 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubation after NIV
Number of subjects: 584
Study 29895612 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients employed at baseline who reported an adverse change in employment after MI (n=492)
Number of subjects: 9319
Study 29895612 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with an adverse change in employment (n=492)
Number of subjects: 9319
Study 29895651 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine consultation for neuropsychiatric symptoms (NPSs) management
Number of subjects: 200
Study 29895651 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control arm)
Number of subjects: 200
Study 29895668 — intervention group
Group type: EXPERIMENTAL
Intervention: Preinfusion CAR product T-cell functionality (measured by T-cell polyfunctionality strength index - PSI)
Number of subjects: 0
Study 29895668 — intervention group
Group type: EXPERIMENTAL
Intervention: Preinfusion CAR product T-cell expansion and pretreatment serum IL-15 levels
Number of subjects: 0
Study 29895668 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyfunctional CD4 T-cells within the total product cell population
Number of subjects: 0
Study 29895702 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation
Number of subjects: 100
Study 29895713 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex coronary lesion geometries (longitudinal eccentricity, cross-sectional eccentricity, surface roughness)
Number of subjects: 1236
Study 29895713 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal longitudinal eccentricity
Number of subjects: 1236
Study 29895713 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual-functional mismatch between coronary angiography and FFR
Number of subjects: 1236
Study 29896154 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosulpiride (75 mg/day orally TID) for 8 weeks (DME and NPDR), 1 week (PDR before vitrectomy), or 12 weeks (DME plus ranibizumab)
Number of subjects: 120
Study 29896154 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose pill, orally TID)
Number of subjects: 120
Study 29896154 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosulpiride (75 mg/day orally TID)
Number of subjects: 120
Study 29896154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 29896450 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program (8-h intensive short-course)
Number of subjects: 176
Study 29896479 — intervention group
Group type: EXPERIMENTAL
Intervention: Rye kernel bread (RKB) evening meals
Number of subjects: 19
Study 29896479 — intervention group
Group type: COMPARATOR
Intervention: White wheat bread (WWB) evening meals
Number of subjects: 19
Study 29896663 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncolytic virotherapy using herpes simplex virus (HSV)
Number of subjects: 0
Study 29897474 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin sensitivity index (ISI)
Number of subjects: 11
Study 29897474 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated 24-hour LH levels
Number of subjects: 11
Study 29897474 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated 24-hour insulin level
Number of subjects: 11
Study 29897482 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryptosporidiosis infection (subclinical)
Number of subjects: 508
Study 29897482 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryptosporidiosis
Number of subjects: 508
Study 29897486 — intervention group
Group type: EXPERIMENTAL
Intervention: Br-E (Habitual breakfast eaters)
Number of subjects: 32
Study 29897486 — intervention group
Group type: COMPARATOR
Intervention: Br-S (Habitual breakfast skippers)
Number of subjects: 32
Study 29897529 — intervention group
Group type: EXPERIMENTAL
Intervention: CFS scores 3-4
Number of subjects: 6156
Study 29897529 — intervention group
Group type: EXPERIMENTAL
Intervention: CFS scores 5-7
Number of subjects: 6156
Study 29897529 — intervention group
Group type: EXPERIMENTAL
Intervention: CFS classes added to EuroSCORE II
Number of subjects: 6156
Study 29897579 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency (ID)
Number of subjects: 1042
Study 29897579 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia
Number of subjects: 1042
Study 29897579 — intervention group
Group type: EXPERIMENTAL
Intervention: Low plasma vitamin B-12
Number of subjects: 1042
Study 29897579 — intervention group
Group type: EXPERIMENTAL
Intervention: Other micronutrient status biomarkers
Number of subjects: 1042
Study 29897841 — intervention group
Group type: EXPERIMENTAL
Intervention: CYD-TDV vaccine
Number of subjects: 0
Study 29897841 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 29898218 — intervention group
Group type: EXPERIMENTAL
Intervention: Martin/Hopkins method for LDL-C estimation
Number of subjects: 12742
Study 29898218 — intervention group
Group type: EXPERIMENTAL
Intervention: Friedewald method for LDL-C estimation
Number of subjects: 12742
Study 29898218 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with PUC LDL-C
Number of subjects: 12742
Study 29898753 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor Residual Spraying (IRS) and Long-Lasting Insecticide-Treated Bednets (LLINs) for malaria control
Number of subjects: 2936
Study 29898753 — intervention group
Group type: COMPARATOR
Intervention: Historical data from 2005-2008 (Control)
Number of subjects: 2936
Study 29898762 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment total hemoglobin (tHb)
Number of subjects: 22
Study 29898762 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle 1 %tHb
Number of subjects: 22
Study 29898762 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle 2 %tHb
Number of subjects: 22
Study 29898762 — intervention group
Group type: COMPARATOR
Intervention: HER2 subtype as a single predictor
Number of subjects: 22
Study 29898762 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tumor subtypes with tHb
Number of subjects: 22
Study 29898763 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive high-frequency oscillatory ventilation (NHFOV)
Number of subjects: 300
Study 29898763 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 300
Study 29898765 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval walking training (3×30-minute sessions/week for 10 weeks)
Number of subjects: 12
Study 29898765 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval walking training
Number of subjects: 12
Study 29898822 — intervention group
Group type: EXPERIMENTAL
Intervention: High UA Z-score
Number of subjects: 8833
Study 29898822 — intervention group
Group type: COMPARATOR
Intervention: Low UA Z-score
Number of subjects: 8833
Study 29898822 — intervention group
Group type: COMPARATOR
Intervention: Normal UA Z-score
Number of subjects: 8833
Study 29898843 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 0
Study 29898843 — intervention group
Group type: COMPARATOR
Intervention: Control (no caffeine)
Number of subjects: 0
Study 29898901 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Glucose Monitors (BGMs) tested in three studies; each BGM tested on average 115 subjects.
Number of subjects: 1035
Study 29898959 — intervention group
Group type: EXPERIMENTAL
Intervention: STAT3 signaling disruption in myeloid cells
Number of subjects: 0
Study 29898959 — intervention group
Group type: COMPARATOR
Intervention: Control mice with intact STAT3 signaling
Number of subjects: 0
Study 29898959 — intervention group
Group type: EXPERIMENTAL
Intervention: STAT3-deficient macrophages
Number of subjects: 0
Study 29898959 — intervention group
Group type: COMPARATOR
Intervention: IL-10 exposure in control BMDMs
Number of subjects: 0
Study 29898959 — intervention group
Group type: EXPERIMENTAL
Intervention: STAT3 deficiency in BMDMs
Number of subjects: 0
Study 29898959 — intervention group
Group type: COMPARATOR
Intervention: Coculture of IL-10-stimulated control BMDMs with fibroblasts
Number of subjects: 0
Study 29898959 — intervention group
Group type: EXPERIMENTAL
Intervention: STAT3 deficiency in BMDMs during coculture
Number of subjects: 0
Study 29899062 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoptive T-cell transfer therapy (ACT) targeting MART1 antigen
Number of subjects: 1
Study 29899081 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustable gastric banding (AGB)
Number of subjects: 61
Study 29899081 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y-gastric bypass (RYGB)
Number of subjects: 61
Study 29899081 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (BS)
Number of subjects: 61
Study 29899212 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedizolid phosphate (once daily for 4 days)
Number of subjects: 18
Study 29899212 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of tedizolid phosphate and pseudoephedrine (60 mg on day 5)
Number of subjects: 18
Study 29899212 — intervention group
Group type: COMPARATOR
Intervention: Placebo (once daily for 4 days)
Number of subjects: 18
Study 29899763 — intervention group
Group type: EXPERIMENTAL
Intervention: PIPAC with oxaliplatin for colorectal PM and cisplatin/doxorubicin for other primary tumors
Number of subjects: 35
Study 29899820 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimeric antigen receptor (CAR) targeting BCMA using a fully human single chain variable fragment (scFv)
Number of subjects: 0
Study 29899820 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemical analysis of normal tissue expression using commercially available polyclonal antibodies
Number of subjects: 0
Study 29899820 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel, fully human scFv binding domains to BCMA generated by screening a naïve B-cell derived phage display library
Number of subjects: 0
Study 29900143 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (2700 mg/day EPA: DHA ratio=2)
Number of subjects: 88
Study 29900143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 29901610 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (CHM)
Number of subjects: 600
Study 29901698 — intervention group
Group type: EXPERIMENTAL
Intervention: High EDIH scores (highest quintile)
Number of subjects: 120401
Study 29901700 — intervention group
Group type: EXPERIMENTAL
Intervention: High-SFA diet (≥22 g/d)
Number of subjects: 80
Study 29901700 — intervention group
Group type: COMPARATOR
Intervention: Low-SFA diet (<22 g/d)
Number of subjects: 80
Study 29901727 — intervention group
Group type: EXPERIMENTAL
Intervention: Overfeeding by 1250 kcal/d for 28 days
Number of subjects: 40
Study 29901727 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat gainers
Number of subjects: 40
Study 29901727 — intervention group
Group type: EXPERIMENTAL
Intervention: Overfeeding
Number of subjects: 40
Study 29901727 — intervention group
Group type: COMPARATOR
Intervention: Insulin infusion at day 0
Number of subjects: 40
Study 29901727 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin at day 28
Number of subjects: 40
Study 29901782 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric Surgery (BS)
Number of subjects: 86
Study 29901782 — intervention group
Group type: COMPARATOR
Intervention: Control (Normal-weight, Overweight, Obese)
Number of subjects: 86
Study 29902036 — intervention group
Group type: EXPERIMENTAL
Intervention: Service user co-facilitated antistigma and mhGAP trainings
Number of subjects: 17
Study 29902097 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron chelation therapy (ICT) using deferasirox
Number of subjects: 0
Study 29902097 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron chelation therapy (ICT)
Number of subjects: 0
Study 29902097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29902683 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 week supervised exercise-aided nicotine replacement therapy (NRT) cessation program
Number of subjects: 413
Study 29902983 — intervention group
Group type: EXPERIMENTAL
Intervention: PRONTO training
Number of subjects: 310
Study 29902983 — intervention group
Group type: COMPARATOR
Intervention: Control (providers who did not attend training)
Number of subjects: 310
Study 29902988 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium-166 radioembolization after peptide receptor radionuclide therapy (PRRT)
Number of subjects: 0
Study 29902988 — intervention group
Group type: COMPARATOR
Intervention: Peptide receptor radionuclide therapy (PRRT)
Number of subjects: 0
Study 29903024 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D index
Number of subjects: 997
Study 29903024 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-VAS score
Number of subjects: 997
Study 29903024 — intervention group
Group type: EXPERIMENTAL
Intervention: Income (< 2000 RMB)
Number of subjects: 997
Study 29903024 — intervention group
Group type: EXPERIMENTAL
Intervention: Income (2000-4999 RMB)
Number of subjects: 997
Study 29903024 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate or severe symptoms of discomfort (more than one symptom)
Number of subjects: 997
Study 29903024 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhosis
Number of subjects: 997
Study 29903024 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperlipidemia
Number of subjects: 997
Study 29903024 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 997
Study 29903024 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease profile
Number of subjects: 997
Study 29903707 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate at 60 mg/kg per day with R-CHOP
Number of subjects: 31
Study 29903707 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP (control group)
Number of subjects: 31
Study 29903793 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (GLM) 50 mg subcutaneously once monthly
Number of subjects: 1458
Study 29903827 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep apnoea (measured by apnoea/hypopnoea index, AHI; mean±sd 15.9±11.5 events·h)
Number of subjects: 226
Study 29903860 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human angiotensin-converting enzyme 2 (rhACE2) at doses of 0.2 or 0.4 mg·kg
Number of subjects: 0
Study 29905488 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) treatment for 8 weeks
Number of subjects: 74
Study 29905808 — intervention group
Group type: EXPERIMENTAL
Intervention: darunavir/ritonavir 400/100 mg q24h
Number of subjects: 15
Study 29905808 — intervention group
Group type: COMPARATOR
Intervention: darunavir/ritonavir 800/100 mg q24h
Number of subjects: 15
Study 29906810 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sutured gastroplasty using a novel suturing device
Number of subjects: 51
Study 29906810 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 51
Study 29907893 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 0.5 mg
Number of subjects: 1612
Study 29907893 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 1.0 mg
Number of subjects: 1612
Study 29907893 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 1612